- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07941778
Ivarmacitinib Treat PMR (ESI-PMR)
Efficacy and Safety of Ivarmacitinib for Polymyalgia Rheumatica (ESI-PMR): A 52-Week Open-Label, Randomized, Controlled Clinical Trial
To evaluate the efficacy of the combination of Ivarmacitinib and short-term glucocorticoid induction for remission and rapid discontinuation of glucocorticoids in the treatment of Polymyalgia rheumatica (PMR) , and to compare the differences in the proportion of patients in remission at weeks 24 between the experimental group and control group.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
PMR is a common inflammatory disorder in older adults (aged >50 years), characterized by pain and stiffness in the neck, shoulder girdle, and pelvic girdle. Systemic glucocorticoid administration is the current standard of care, achieving rapid control of inflammation and symptom alleviation. However, standard regimens require prolonged administration (at least 12 months) and are associated with a high rate of relapse during steroid tapering. In this vulnerable population with a high burden of baseline chronic comorbidities (e.g., osteoporosis, diabetes, cardiovascular disease), sustained glucocorticoid use frequently leads to severe adverse effects, such as steroid-induced osteoporosis, peptic ulceration, hyperglycemia, glaucoma, opportunistic infections, and metabolic dysregulation. Consequently, there is an urgent need to explore safer, more effective, and more accessible therapeutic strategies.
Ivarmacitinib, a highly selective JAK1 inhibitor, is approved for rheumatoid arthritis and ankylosing spondylitis, but remains unapproved for PMR. Thus, this protocol represents an investigator-initiated off-label study. Accumulated evidence indicates that JAK1 inhibition holds substantial potential for controlling PMR disease activity and facilitating steroid tapering. To address the current lack of high-level clinical evidence, this study was initiated to assess the 52-week efficacy and safety of ivarmacitinib in patients with PMR.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Weiqian Chen Dr. Chen, Doctor
- Numéro de téléphone: 860571-87233418
- E-mail: cwq678@zju.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Xinxin Han Dr. Han, Doctor
- Numéro de téléphone: 860571-87233418
- E-mail: hxx1992@126.com
Lieux d'étude
-
-
Zhejiang
-
Anji, Zhejiang, Chine
- Anji People's Hospital
-
Contact:
- Chunyan Chen Dr. Chen
- Numéro de téléphone: +8618167257305
- E-mail: 375709261@qq.com
-
Haining, Zhejiang, Chine
- Haining Kanghua Hospital
-
Contact:
- Jiantao Sun Dr. Sun
- Numéro de téléphone: +8615967333501
- E-mail: 5598338@qq.com
-
Hangzhou, Zhejiang, Chine
- the First Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Weiqian Chen Dr. Chen, Doctor
- Numéro de téléphone: 860571-87233418
- E-mail: cwq678@zju.edu.cn
-
Huzhou, Zhejiang, Chine
- Huzhou First People's Hospital
-
Contact:
- Min Ding Dr. Ding
- Numéro de téléphone: +8615805827300
- E-mail: 1943902345@qq.com
-
Wenzhou, Zhejiang, Chine
- Wenzhou People's Hospital
-
Contact:
- Suxian Lin Dr. Lin
- Numéro de téléphone: 8613957741565
- E-mail: 4268945@qq.com
-
Yiwu, Zhejiang, Chine
- the Fourth Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Jie Chang Dr. Chang
- Numéro de téléphone: 8613705790575
- E-mail: changjie7311@163.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- patients who fulfilled the 2012ACR/EULAR criteria for PMR;
- Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS > 10,
- Adults age 50-88, Weight 45-85Kg,
- ESR>40mm/h or CRP >50mg/L(5mg/dl),
- Informed consent.
Exclusion Criteria:
- Patients with known allergies to Ivarmacitinib, prednisone or methylprednisolone,
- Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,
- Patients with severe osteoarthritis,
- Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),
- Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,
- Patients with abnormal liver function (ALT/AST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate <60); hyperlipidemia not improved by lipid-lowering drugs,
- Pregnant or lactating women,
- Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),
- Patients with previous visual field disorder or single eye dysfunction, cataract patients,
- Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,
- For patients with abnormal blood routine, lymphocytes <500/mm3 or ANC <1000/mm3 or HGB < 90g/L,
- Patients with active bleeding and peptic ulcer,
- Have used biological agents or added azathioprine, FK506 within 1 month before enrollment,
- Those who have participated in other drug clinical trials within 4 weeks
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ivarmacitinib
Withdrawal of prednisone within 8 weeks: 15mg daily for 2 weeks, 10mg daily for 4 weeks, 5mg daily for 2 weeks, then discontinue; Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
Withdrawal of prednisone within 8 weeks. Take Ivarmacitinib 4mg daily for 24 weeks, then 2mg daily for 28 weeks. |
|
Comparateur actif: Prednisone
Prednisone 15mg daily was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-8 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 10 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. |
The dose of Prednisone was gradually tapered. Once relapse occurred, the dose increased to the pre-relapse dose. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of patients in remission at weeks 24
Délai: at weeks 24
|
Proportion of patients in remission at weeks 24 |
at weeks 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of patients in remission at weeks 52
Délai: at weeks 52
|
Proportion of patients in remission at weeks 52 |
at weeks 52
|
|
PMR-AS score at weeks 24
Délai: at weeks 24
|
PMR-AS score: CRP (mg/dL)+Patient self-evaluation (0-10 visual scale)+ Physician global assessment (0-10 Visual Scale)+[morning stiffness (min) x0.1]+ EUL (0-3). |
at weeks 24
|
|
CRP at weeks 24
Délai: at weeks 24
|
CRP at weeks 24 |
at weeks 24
|
|
ESR at weeks 24
Délai: at weeks 24
|
ESR at weeks 24 |
at weeks 24
|
|
Relapse rate within 52 weeks
Délai: within 52 weeks
|
Relapse rate within 52 weeks |
within 52 weeks
|
|
Relapse times within 52 weeks
Délai: within 52 weeks
|
Relapse times within 52 weeks |
within 52 weeks
|
|
Cumulative dose of prednisone within 52 weeks
Délai: within 52 weeks
|
Cumulative dose of prednisone within 52 weeks |
within 52 weeks
|
|
Cumulative dose of MTX within 52 weeks
Délai: within 52 weeks
|
Cumulative dose of MTX within 52 weeks |
within 52 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Jin Lin, Prof., First Affiliated Hospital of Zhejiang University
Publications et liens utiles
Publications générales
- Camellino D, Dejaco C, Martini F, Cosso R, Bianchi G. Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1796. Epub 2024 Oct 28.
- Liu X, Xu L, Zhao C, Liu S, Sun L, Yang L, Xu X, Wu R, Liu X, Zhang J, Xu S, Zhu P, Chen H, Wang X, Lin C, Lin J, Zhan F, Wei H, Huang Q, Liu H, Ma X, Shi G, Lu Y, Geng X, Jiang Z, Zhang N, Tang K, Zhang R, Zhao Y, Xue L, Song S, Shi X, Zhang Z, Liu P, Wang H, Li Z. Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. Arthritis Rheumatol. 2025 Nov;77(11):1512-1523. doi: 10.1002/art.43238. Epub 2025 Aug 5.
- Xu X, Wei H, Liu L, Yang R, Shi Q, Pang D. Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. Front Pharmacol. 2025 Nov 20;16:1710434. doi: 10.3389/fphar.2025.1710434. eCollection 2025.
- Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial. Ann Rheum Dis. 2025 Feb;84(2):188-200. doi: 10.1136/ard-2024-226385. Epub 2025 Jan 3.
- Ma X, Yang F, Wu J, Xu B, Jiang M, Sun Y, Sun C, Yu Y, Xu D, Xiao L, Ren C, Chen C, Ye Z, Liang J, Lin J, Chen W. Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial. PLoS Med. 2023 Jun 29;20(6):e1004249. doi: 10.1371/journal.pmed.1004249. eCollection 2023 Jun.
- Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial. JAMA. 2022 Sep 20;328(11):1053-1062. doi: 10.1001/jama.2022.15459.
- Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016 Jun 14;315(22):2442-58. doi: 10.1001/jama.2016.5444.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IIT20260100C-R1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Due to the policies of the country, it is not possible to directly share the personal data of the subjects. If the researchers are interested, they can contact the relevant person via email to obtain the summarized data.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .